Squires Says Biocon Challenge To Eylea Patent Filed Too Late
U.S. Patent and Trademark Office Director John Squires has explained why he rejected Biocon Biologics' challenge to a Regeneron Pharmaceuticals Inc. patent covering the eye disorder drug Eylea — because Biocon...To view the full article, register now.
Already a subscriber? Click here to view full article